This systematic literature review reports incidence of adverse drug effects associated with guideline-directed medical therapy for patients with heart failure with reduced ejection fraction.
Ralph J. Riello III, PharmD
Advertisement
Articles by Ralph J. Riello III, PharmD
Best Practices for Implementing Venous Thromboembolism Prophylaxis Across the Continuum of Care
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
The Use of Betrixaban for Extended Prophylaxis of Venous Thromboembolism Events in Hospitalized, High-Risk Patients
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis
ByPaul P. Dobesh, PharmD,Tania Ahuja, PharmD,George A. Davis, PharmD,Hugh Fatodu, MBA, RPh,William H. Francis, MBA, RPh,Frank P. Hull, MD,Gary L. Johnson, MD, MS, MBA,Joshua D. Lenchus, DO, BSPharm,Jacqueline Glee Lenoir, PharmD,Claudette McPherson, RN, BSN,Jeffrey Nemeth, PharmD, MPA,Ralph J. Riello III, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5